Pancreatic Cancer Research

ResearcherBoston UniversityActive in the last 2 years

Péter Jenő Hegyi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0399-7259; OpenAlex author ID A5071674782, A5108326896, A5140188488. Sources: OpenAlex.

Their work

Papers
25 (first author 0, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
80
Papers, trials and grants by year

2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: none · 2019: 4 papers · 2020: 2 papers · 2021: 4 papers · 2022: 4 papers · 2023: 2 papers · 2024: 2 papers · 2025: 1 paper · 2026: 2 papers

Papers 25

  1. One out of four patients with pancreatic cancer experience psychological symptoms: A systematic review and meta-analysis. Last author DOI 10.1371/journal.pone.0348435↗
  2. Cardiovascular Risk in Pancreatic Cancer: A Meta-Analysis of 197 Studies. Last author DOI 10.3390/cancers18071108↗
  3. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  4. Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk. Co-author DOI 10.1002/ijc.35046↗
  5. Investigating the influence of taurochenodeoxycholic acid (TCDCA) on pancreatic cancer cell behavior: An RNA sequencing approach. Co-author DOI 10.1016/j.jbiotec.2024.05.010↗
  6. A scan of all coding region variants of the human genome, identifies 13q12.2-rs9579139 and 15q24.1-rs2277598 as novel risk loci for pancreatic ductal adenocarc… Co-author DOI 10.1093/carcin/bgad056↗
  7. Exploring the Neandertal legacy of pancreatic ductal adenocarcinoma risk in Eurasians. Co-author DOI 10.1186/s40659-023-00457-y↗
  8. Prognostic role of cell-free DNA biomarkers in pancreatic adenocarcinoma: A systematic review and meta-analysis. Last author DOI 10.1016/j.critrevonc.2021.103548↗
  9. Common variability in oestrogen-related genes and pancreatic ductal adenocarcinoma risk in women. Co-author DOI 10.1038/s41598-022-22973-9↗
  10. Role of stereotactic body radiation in the enhancement of the quality of life in locally advanced pancreatic adenocarcinoma: a systematic review. Co-author DOI 10.1186/s13014-022-02076-5↗
  11. Preoperative Serum Carbohydrate Antigen 19-9 Levels Cannot Predict the Surgical Resectability of Pancreatic Cancer: A Meta-Analysis. Co-author DOI 10.3389/pore.2022.1610266↗
  12. Genome-wide scan of long noncoding RNA single nucleotide polymorphisms and pancreatic cancer susceptibility. Co-author DOI 10.1002/ijc.33475↗
  13. Polygenic and multifactorial scores for pancreatic ductal adenocarcinoma risk prediction. Co-author DOI 10.1136/jmedgenet-2020-106961↗
  14. Association of Genetic Variants Affecting microRNAs and Pancreatic Cancer Risk. Co-author DOI 10.3389/fgene.2021.693933↗
  15. Identification of Recessively Inherited Genetic Variants Potentially Linked to Pancreatic Cancer Risk. Co-author DOI 10.3389/fonc.2021.771312↗
  16. Genome-wide association study identifies an early onset pancreatic cancer risk locus. Co-author DOI 10.1002/ijc.33004↗
  17. Bile accelerates carcinogenic processes in pancreatic ductal adenocarcinoma cells through the overexpression of MUC4. Co-author DOI 10.1038/s41598-020-79181-6↗
  18. Genetic determinants of telomere length and risk of pancreatic cancer: A PANDoRA study. Co-author DOI 10.1002/ijc.31928↗
  19. Germline BRCA2 K3326X and CHEK2 I157T mutations increase risk for sporadic pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/ijc.32127↗
  20. Genetic variability of the ABCC2 gene and clinical outcomes in pancreatic cancer patients. Co-author DOI 10.1093/carcin/bgz006↗
  21. Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations. Co-author DOI 10.1136/gutjnl-2017-314828↗
  22. Efficacy and Safety of FOLFIRINOX in Locally Advanced Pancreatic Cancer. A Single Center Experience. Co-author DOI 10.1007/s12253-016-0176-0↗
  23. A Common CCK-B Receptor Intronic Variant in Pancreatic Adenocarcinoma in a Hungarian Cohort. Co-author DOI 10.1097/mpa.0000000000000539↗
  24. Pancreatic Cancer: Multicenter Prospective Data Collection and Analysis by the Hungarian Pancreatic Study Group. Co-author DOI 10.15403/jgld.2014.1121.252.pcr↗
  25. [Pancreatic cancer. Evidence based management guidelines of the Hungarian Pancreatic Study Group]. Co-author DOI 10.1556/oh.2015.30063↗

Closest collaborators

The 25 strongest of 80 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Ștefania Bunduc · 2 shared papers, 2022–2026 · strength 0.41
  2. Eleonóra Gál · 2 shared papers, 2020–2024 · strength 0.35
  3. Viktória Venglovecz · 2 shared papers, 2020–2024 · strength 0.35
  4. Zoltán Veréb · 2 shared papers, 2020–2024 · strength 0.35
  5. Ákos Szűcs · 4 shared papers, 2015–2022 · strength 0.31
  6. Anna Sára Bognár · 1 shared paper, 2026 · strength 0.29
  7. Brigitta Teutsch · 1 shared paper, 2026 · strength 0.29
  8. Jázmin Németh · 1 shared paper, 2026 · strength 0.26
  9. Jimin Lee · 1 shared paper, 2026 · strength 0.26
  10. Shahram Parvaneh · 1 shared paper, 2024 · strength 0.24
  11. László Czakó · 4 shared papers, 2015–2020 · strength 0.24
  12. Gábor Lakatos · 3 shared papers, 2016–2019 · strength 0.18
  13. Federico Canzian · 2 shared papers, 2019–2022 · strength 0.16
  14. Giulia Martina Cavestro · 2 shared papers, 2019–2022 · strength 0.16
  15. Rita Teresa Lawlor · 2 shared papers, 2019–2022 · strength 0.16
  16. Renata Talar‐Wojnarowska · 2 shared papers, 2019–2022 · strength 0.16
  17. John P. Neoptolemos · 2 shared papers, 2019–2022 · strength 0.16
  18. Gabriele Capurso · 2 shared papers, 2019–2022 · strength 0.16
  19. Daniele Campa · 2 shared papers, 2019–2022 · strength 0.16
  20. Francesca Tavano · 2 shared papers, 2019–2022 · strength 0.16
  21. Manuel Gentiluomo · 2 shared papers, 2019–2022 · strength 0.16
  22. Pavel Souček · 2 shared papers, 2019–2022 · strength 0.16
  23. Raffaele Pezzilli · 2 shared papers, 2019–2022 · strength 0.16
  24. Hermann Brenner · 2 shared papers, 2019–2022 · strength 0.15
  25. Ivonne Regel · 1 shared paper, 2022 · strength 0.15

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.